HIV-1 Disease Progression and Drug Resistance Mutations among Children on First-Line Antiretroviral Therapy in Ethiopia
-
Published:2023-08-18
Issue:8
Volume:11
Page:2293
-
ISSN:2227-9059
-
Container-title:Biomedicines
-
language:en
-
Short-container-title:Biomedicines
Author:
Getaneh Yimam12ORCID, Getnet Fentabil23, Ning Feng4, Rashid Abdur5, Liao Lingjie6, Yi Feng6, Shao Yiming16
Affiliation:
1. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310027, China 2. Ethiopian Public Health Institute, Addis Ababa P.O. Box 1242, Ethiopia 3. Takemi Program in International Health, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA 4. Chinese Center for Disease Control and Prevention, Beijing 102206, China 5. School of Medicine, Nankai University, Tianjin 300071, China 6. State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
Abstract
Background: High rates of disease progression and HIV drug resistance (HIVDR) among adults taking highly active antiretroviral treatment (HAART) in Sub-Saharan Africa were previously documented. However, children were generally not considered despite their greater risk. Hence, this study was aimed to evaluate HIV-1 disease progression and drug resistance mutation among children on first-line antiretroviral therapy in Ethiopia. Method: A longitudinal study was conducted among 551 HIV-positive children (<15 years old) recruited between 2017 and 2019 at 40 antiretroviral treatment delivery sites in Ethiopia. Disease progression was retrospectively measured over a 12-year (2007–2019) follow-up as the progress towards immunosuppression. Two consecutive viral load (VL) tests were conducted in 6-month intervals to assess virologic failure (VF). For children with VF, HIV-1 genotyping and sequencing was performed for the pol gene region using in-house assay validated at the Chinese Center for Disease Control and Prevention, and the Stanford HIVDB v9.0 algorithm was used for identification of drug resistance mutations. The Kaplan–Meier analysis and Cox proportional hazards regression model were used to estimate the rate and predictors of disease progression, respectively. Results: The disease progression rate was 6.3 per 100 person-years-observation (95% CI = 4.21–8.53). Overall immunosuppression (CD4 count < 200 cells/mm3) during the 12-year follow-up was 11.3% (95% CI = 7.5–15.1). Immunosuppression was significantly increased as of the mean duration of 10.5 (95% CI = 10.1–10.8) years (38.2%) to 67.8% at 12 years (p < 0.001). Overall, 14.5% had resistance to at least one drug, and 6.2% had multi-drug resistance. A resistance of 67.8% was observed among children with VF. Resistance to non-nucleotide reverse transcriptase inhibitors (NNRTI) and nucleotide reverse transcriptase inhibitors (NRTI) drugs were 11.4% and 10.1%, respectively. Mutations responsible for NRTI resistance were M184V (30.1%), K65R (12.1%), and D67N (5.6%). Moreover, NNRTI-associated mutations were K103N (14.8%), Y181C (11.8%), and G190A (7.7%). Children who had a history of opportunistic infection [AHR (95% CI) = 3.4 (1.8–6.2)], vitamin D < 20 ng/mL [AHR (95% CI) = 4.5 (2.1–9.9)], drug resistance [AHR (95% CI) = 2.2 (1.4–3.6)], and VF [AHR (95% CI) = 2.82 (1.21, 3.53)] had a higher hazard of disease progression; whereas, being orphan [AOR (95% CI) = 1.8 (1.2–3.1)], history of drug substitution [(AOR (95% CI) = 4.8 (2.1–6.5), hemoglobin < 12 mg/dL [AOR (95% CI) = 1.2 (1.1–2.1)] had higher odds of developing drug resistance. Conclusions: Immunosuppression was increasing over time and drug resistance was also substantially high. Enhancing routine monitoring of viral load and HIVDR and providing a vitamin-D supplement during clinical management could help improve the immunologic outcome. Limiting HAART substitution is also crucial for children taking HAART in Ethiopia.
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference37 articles.
1. UNAIDS (2023). Global AIDS Monitoring 2023, UNAIDS. Available online: https://indicatorregistry.unaids.org/sites/default/files/2023-global-aids-monitoring_en.pdf. 2. Ethiopian Public Health Institute (2023, April 11). Ethiopia Population-Based HIV Impact Assessment. Final Report, Volume 3, August 2020. Available online: https://phia.icap.columbia.edu/wpcontent/uploads/2020/11/EPHIA_Report_280820_Web.pdf. 3. Zhou, Z., Wagar, N., DeVos, J.R., Rottinghaus, E., Diallo, K., Nguyen, D.B., Bassey, O., Ugbena, R., Wadonda-Kabondo, N., and McConnell, M.S. (2011). Optimization of a Low Cost and Broadly Sensitive Genotyping Assay for HIV-1 Drug Resistance Surveillance and Monitoring in Resource-Limited Settings. PLoS ONE, 6. 4. Federal Ministry of Health Ethiopia (2017). National Guidelines for Comprehensive HIV Prevention, Care and Treatment, Federal Ministry of Health. Available online: https://www.childrenandaids.org/sites/default/files/2018-05/Ethiopia_Nat%20GuidelinesART_2017.pdf. 5. Predictors of disease progression in HIV infection: A review;Langford;AIDS Res. Ther.,2007
|
|